From Bench To Bedside And Back Again: Car T Cell Signaling And Survival

Loading...
Thumbnail Image
Degree type
Doctor of Philosophy (PhD)
Graduate group
Cell & Molecular Biology
Discipline
Subject
4-1BB
Chimeric antigen receptor
Non-canonical NF-kB
T cell
Allergy and Immunology
Cell Biology
Immunology and Infectious Disease
Medical Immunology
Oncology
Funder
Grant number
License
Copyright date
2020-02-07T20:19:00-08:00
Distributor
Related resources
Author
Philipson, Benjamin
Contributor
Abstract

Chimeric Antigen Receptor (CAR) T cell therapies for hematologic malignancies have been astonishingly successful in driving cancer remissions. However, early loss of CAR T cells and return of normal B cells is a predictor of relapse in pediatric acute lymphoblastic leukemia; the duration of remission is associated with the persistence of CAR T cells for more than three months. These CAR T cells are the product of over 30 years of research and innovation in T cell biology and engineering, which began with the desire to understand how the T cell receptor (TCR) activates T cells in response to antigen. In this thesis, we return to that approach again, but this time to investigate signaling downstream of the costimulatory receptor, 4-1BB, a TNF Receptor Superfamily (TNFRSF) member. 4-1BB-costimulated CAR (BBz) T cells exhibit longer persistence following adoptive transfer than CD28-costimulated CAR (28z) T cells, which contain the first costimulatory domain commonly added to CARs. 4-1BB signaling improves T cell persistence even in the context of 28z CAR activation, which indicates that the 4-1BB cytoplasmic domain contributes unique pro-survival signals. In order to specifically study CAR signaling, we developed a cell-free ligand-based activation and ex vivo culture system for CD19-specific CAR T cells. In this system, we observed greater ex vivo expansion and survival of BBz CAR T cells compared to 28z T cells. We used this system to isolate a pathway activated most by BBz CARs, the non-canonical NF-kB (ncNF-kB) pathway, which is associated with the survival benefit from imparted by other TNFRSFs. We observed that BBz CARs uniquely activate non-canonical NF-kB (ncNF- kB) signaling in T cells basally, and the anti-CD19 BBz CAR further enhances ncNF-kB signaling following ligand engagement. Reducing ncNF-kB signaling specifically diminishes anti-CD19 BBz T cell expansion and survival and is associated with a significant increase in expression of the most pro-apoptotic isoforms of Bim. Although our findings do not exclude the importance of other signaling differences between these CARs, they demonstrate the necessary and non-redundant role of ncNF-kB signaling in promoting BBz CAR T cell survival that likely underlies the engraftment persistence observed with this CAR design.

Advisor
Michael C. Milone
Steven M. Albelda
Date of degree
2019-01-01
Date Range for Data Collection (Start Date)
Date Range for Data Collection (End Date)
Digital Object Identifier
Series name and number
Volume number
Issue number
Publisher
Publisher DOI
Journal Issue
Comments
Recommended citation